CoChat

Translational Medicine Lessons from Flurizan's Failure in Alzheimer's Disease (AD) Trial: Implication for Future Drug Discovery and Development for AD

Open access
Wan, Hong I., Jacobsen, J. Steve, Rutkowski, J. Lynn, Feuerstein, Giora Z. · 2009 · Clinical and Translational Science
Cited by 30

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Alzheimer's disease (AD) is a progressive and fatal brain disease. According to the Alzheimer's Association, as many as 5.2 million people in the United States are living with AD and 10 million "baby boomers" are expected to develop the disease in their lifetime. AD is the sixth leading cause of death, and the direct and indirect costs of dementia amount to more than $148 billion each year (2008 Alzheimer's Disease Facts and Figures, Alzheimer's Association). Currently, there is no cure. To date, the U.S. Food and Drug Administration (FDA) has approved three cholinesterase inhibitors (donepezil, galantamine, and rivastigmine) and an N-methylD-aspartate (NMDA) receptor antagonist (memantine) that offer modest improvement in cognitive function in some individuals, but such treatments are often discontinued within 6 months because of inadequate efficacy and/or tolerability issues. Although treatments with the potential to modify the course of AD by affecting the underlying pathophysiology are rapidly evolving and several of them have entered advanced phases of human clinical trials, none has shown convincing clinical efficacy in a large pivotal trial. The recent announcement from Myriad Pharmaceuticals, Inc. (Salt Lake City, UT, USA) on June 30, 2008, that Flurizan (Tarenflurbil, MPC-7869) failed to demonstrate statistically significant efficacy in either of the co-primary endpoints in the phase III trial represents another high-profile failure in the pursuit of disease-modifying therapeutics for AD. It is believed that on the basis of this result, Myriad and partner Lundbeck decided to discontinue the development of Flurizan, including the ongoing international phase III trial, which was due to complete in October. This phase III trial followed 1,684 AD patients over an 18-month treatment period for a change in the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) score (a cognitive measure) and Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ACDS-ADL) score (a functional measure) relative to placebo as the efficacy endpoints. As this trial was powered to achieve statistical significance in a nonclinically significant change in the ADAS-Cog score, the failure confirms that Flurizan has no clinical effect beyond the standard of care (and placebo). Prior to Myriad's announcement, the most recent failure was tramiprosate (Alzhemed), developed by Neurochem (Laval, Quebec, Canada), which was supposed to act by binding soluble amyloid Aβ peptides. It was terminated in August 2007 again after a large phase III trial that included over 1,800 AD patients treated for 18 months showed no statistical significant difference b etween treatment and placebo groups in both primary efficacy endpoints of the ADAS-Cog and Disability Assessment for Dimentia (DAD). These two large clinical trials with compounds reputed for their antiamyloid mechanism of action were disappointing news to the AD community, especially for the patients and caregivers who are desperately waiting for a disease-modifying therapy that would offer some hope for disease slowing beyond the short-term symptomatic relief. In this commentary, we offer a translational medicine perspective on the choices made to select and develop these compounds for AD treatment. A close examination of the Flurizan case presented below could provide important insights and "lessons learned," especially regarding the issues of evidence-based clinical decision making during the drug development program. This case study highlights the importance of appropriate and rigorous use of biomarkers in AD drug development. We take the position, based on our analysis and available literature, that these compounds are inadequate tools to fully investigate the role of amyloid pathways in AD. We further recommend a biomarker-driven roadmap that could be used at different stages to reduce the risk of development of innovative compounds based on a new mechanism of action in the AD program. It is widely recognized that today's environment for a new pharmaceutical development is increasingly challenging, particularly since many new targets are not as well validated. In response to this challenge, the pharmaceutical industry is increasingly using biomarkers as rationales and potentially cost-effective means of predicting potential success of novel therapeutics in drug discovery and development. Biomarkers can be employed to (1) understand the relevance of the drug target to human disease, (2) demonstrate drug-target interaction, (3) measure the consequences of target modulation (pharmacodynamic [PD] effects), (4) detect modulation of pathophysiological processes, and (5) optimize patient selection to detect medical benefits. The use of such evidence-based biomarkers can increase confidence during early development, improve the ability to prioritize clinical drug candidates across a broad portfolio, and yield better and more cost-effective advancement decis

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1752-8062.2009.00121.x

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 30

Metadata

Authors
Wan, H. I., Jacobsen, J. S., Rutkowski, J. L., & Feuerstein, G. Z.
Venue
Clinical and Translational Science
Publisher
Wiley
Published
2009-06
Volume
2
Issue
3
Pages
242-247
ISSN
  • 1752-8054 (ISSN-L)
  • 1752-8062
OpenAlex
W2014141048
Cited by
30
References
9
FWCI
0.79
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Translational Medicine Lessons from Flurizan's Failure in Alzheimer's Disease (AD) Trial: Implication for Future Drug Discovery and Development for AD. https://app.cochat.ai/papers/10.1111/j.1752-8062.2009.00121.x
The paper
Wan, H. I., Jacobsen, J. S., Rutkowski, J. L., & Feuerstein, G. Z. (2009). Translational Medicine Lessons from Flurizan's Failure in Alzheimer's Disease (AD) Trial: Implication for Future Drug Discovery and Development for AD. Clinical and Translational Science. https://doi.org/10.1111/j.1752-8062.2009.00121.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.